BibTex RIS Kaynak Göster

-

Yıl 2007, Cilt: 20 Sayı: 2, 75 - 84, 25.06.2015

Yaşar Beduk Nural Bekiroğlu Atif Akdaş Haluk Özen Tarık Esen Cavit Can Levent Türkeri

Öz

-

Anahtar Kelimeler

-

Kaynakça

  • 1. Anderson J. Treatment of prostate cancer-The role of primary hormonal therapy. Eur Urol 2003; 132-139.
  • 2. Huggins C, Hodges CV. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1:293-297.
  • 3. The Veterans Administration Co-operative Urological Research Group (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967;124:1011-1017.
  • 4. Vogelzang NJ, Chodak GW, Soloway MS, et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer:final results of a randomized trial; Zoladex Prostate Study Group. Urology 1995; 46:220-226.
  • 5. Kaisary AV, Tyrell CJ, Peeling WB, Griffiths K (1997) Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostate carcinoma. Br J Urol 1997; 32:391-396
  • 6. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 2000;355:1991-1998.
  • 7. Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU, European Urology Update Series 2003; 9:455-461.
  • 8. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: Current status and future prospects. The Prostate 2004; 61:332-353.
  • 9. Iversen P, Melezinek I, Schmidt A. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU International 2001; 87:47-56.
  • 10. Maatman TJ, Gupta MK, Montie JE. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate. J Urol 1985;133:620-621.
  • 11. Chodwick DJ,Gillatt DA,Gingell JC.Medical or surgical orchiectomy:The patients’ choice.BMJ1991; 302:372.
  • 12. The Leuprolide Study Group Group. Leuprolide versus diethylstillbestrol for metastatic prostate cancer. N Eng J Med 1984; 311:1281-1286.
  • 13. Chang A, Yeap B, Davis T, et al. (1996) Doubleblind,randomized study of primary hormonal teratment of stage D2 prostate carcinoma: Flutamide versus diethylstilbestrol. J Clin Oncol 1996; 14:2250-2257.
  • 14. Labrie F, Belanger A, Susan L, et al. History of LHRH agonist and combination therapy in prostate cancer. Endoc Relat Cancer 1996; 3:243-278.
  • 15. Stege R. Potantial side effects of endocrine treatment of long duration in prostate cancer. Prostate 2000; (Suppl 10):38-42.
  • 16. Miyomoto H, Chang C. Antiandrogens fail to block andrositenedione-mediated mutated androgen receptor transactivation in human prostate cancer cells. Int J Urol 2000; 7:32-34.
  • 17. Galler J. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer. Semin Oncol (Suppl 1) 1985;12::28-35.
  • 18. Schröder FH. Endocrine treatment of prostate cancerrecent developments and the future. Part 1: MAB, early vs delayed endocrine treatment and side-effects. BJU International 1999; 83:161-170.
  • 19. Crawford ED, Eisenberger MA, Spaulding JT, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Eng J Med 1989;321:419- 424.
  • 20. Denis LJ, Whelan P, deMoura JCL, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853). Urology 1993;42:119- 132.
  • 21. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Eng L Med 1998; 339:1036-1042 .
  • 22. Tyrrell CJ, Kaisary AV, Iversen P et al. A randomized comparison of Casodex (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33:447-456.
  • 23. Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150 mg-monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer:results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998; 51:389-396.
  • 24. Boccardo F, Barichello M, Battaglia M, et al. Italian Prostate Cancer Group.Bicalutamide monotherapy versus Flutamide plus Goserelin in Prostate Cancer: Updated results of a multicentric trial. Eur Urol 2002; 42:481-490.
  • 25. Sciarra A, Cardi A, DiSilverio F. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer. Urol Int 2004; 72:91-98.
  • 26. Goldenberg SL, Bruchovsky N. Use of ciproterone acetate in prostate cancer. Urol Clin North Am 1991;18:111-112.
  • 27. Pavone-Macaluso M, de Voogt HJ, Viggiano G., et al. Comparison of DES, CPA and medroxyprogestrone acetate in the treatment of advanced prostatic cancer:final analysis of a randomized phase III trial of the European Organization for research on treatment of cancer urological group. J Urol 1986;136:624-631.
  • 28. Moffat LE. Comparison of Zoladex, DES and CPA treatment in advanced prostate cancer. Eur Urol 18(Suppl 3):26-27.
  • 29. Thorpe SC, Azmatullah S, Fellows GJ, O’Boyle PJ. A prospective, randomized study to compare goserelin acetate versus cyproterone acetate versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 1996; 29:47-54.
  • 30. Appu S, Lawrentschuk N, Grills RJ, Neerhut G. Effectiveness of CPA in achieving castration and preventing LHRH analogue induced testosterone surge in patients with prostate cancer. J Urol 2005;174:140- 142.
  • 31. Schröder FH, Whelan P, de Reijke TM, et al. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the EORTC protocol 30892. Eur Urol 2004;45:457-464.

METASTATİK PROSTAT KANSERİNDE CYPROTERONE ACETATE VE KASTRASYON MONOTERAPİLERİNİN ETKİNLİĞİNİN KARŞILAŞTIRMASI: ÇOK MERKEZLİ BİR TÜRK ÜRO-ONKOLOJİ GRUBU ÇALIŞMASI

Yıl 2007, Cilt: 20 Sayı: 2, 75 - 84, 25.06.2015

Yaşar Beduk Nural Bekiroğlu Atif Akdaş Haluk Özen Tarık Esen Cavit Can Levent Türkeri

Öz

Amaç: İlerlemiş prostat kanserinde tibbi veya cerrahi kastrasyon ile CPA’yi karşılatırmak ve CPA’nin terapötik etkisini ortaya koymak. Gereç ve Yöntem: Ondokuz Üroloji Merkezi’ne başvuran T1-4N+MX veya T1-4NXM+ evreli prostat adenokanserli hastalar çalışmaya alınmıştır. Toplam 120 hasta, CPA 3X100mg/gün (Grup1) ve tıbbi veya cerrahi kastarasyon (Grup 2) gruplarına rastgele dağıtılmışlardır. Bu denemenin birincil son noktaları genel ve hastalığa-özel sağkalım olasılıklarıdır. Progresyonsuz sağkalım (PSA progresyon zamanı) ve testesteron düşüş hızı ikincil son noktalar olarak kabul edilmiştir.Progresyonsuz sağkalım olasılıkları Kaplan-Meier metoduyla hesaplanmış ve Logrank testiyle de sağkalım olasılıkları karşılaştırılmıştır.

Anahtar Kelimeler: Prostat kanseri,CPA,Kastrasyon,PSA-progresyon,Sağkalım

Anahtar Kelimeler

Prostat kanseri CPA Kastrasyon PSA-progresyon Sağkalım

Kaynakça

  • 1. Anderson J. Treatment of prostate cancer-The role of primary hormonal therapy. Eur Urol 2003; 132-139.
  • 2. Huggins C, Hodges CV. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1:293-297.
  • 3. The Veterans Administration Co-operative Urological Research Group (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967;124:1011-1017.
  • 4. Vogelzang NJ, Chodak GW, Soloway MS, et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer:final results of a randomized trial; Zoladex Prostate Study Group. Urology 1995; 46:220-226.
  • 5. Kaisary AV, Tyrell CJ, Peeling WB, Griffiths K (1997) Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostate carcinoma. Br J Urol 1997; 32:391-396
  • 6. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 2000;355:1991-1998.
  • 7. Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU, European Urology Update Series 2003; 9:455-461.
  • 8. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: Current status and future prospects. The Prostate 2004; 61:332-353.
  • 9. Iversen P, Melezinek I, Schmidt A. Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function. BJU International 2001; 87:47-56.
  • 10. Maatman TJ, Gupta MK, Montie JE. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate. J Urol 1985;133:620-621.
  • 11. Chodwick DJ,Gillatt DA,Gingell JC.Medical or surgical orchiectomy:The patients’ choice.BMJ1991; 302:372.
  • 12. The Leuprolide Study Group Group. Leuprolide versus diethylstillbestrol for metastatic prostate cancer. N Eng J Med 1984; 311:1281-1286.
  • 13. Chang A, Yeap B, Davis T, et al. (1996) Doubleblind,randomized study of primary hormonal teratment of stage D2 prostate carcinoma: Flutamide versus diethylstilbestrol. J Clin Oncol 1996; 14:2250-2257.
  • 14. Labrie F, Belanger A, Susan L, et al. History of LHRH agonist and combination therapy in prostate cancer. Endoc Relat Cancer 1996; 3:243-278.
  • 15. Stege R. Potantial side effects of endocrine treatment of long duration in prostate cancer. Prostate 2000; (Suppl 10):38-42.
  • 16. Miyomoto H, Chang C. Antiandrogens fail to block andrositenedione-mediated mutated androgen receptor transactivation in human prostate cancer cells. Int J Urol 2000; 7:32-34.
  • 17. Galler J. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer. Semin Oncol (Suppl 1) 1985;12::28-35.
  • 18. Schröder FH. Endocrine treatment of prostate cancerrecent developments and the future. Part 1: MAB, early vs delayed endocrine treatment and side-effects. BJU International 1999; 83:161-170.
  • 19. Crawford ED, Eisenberger MA, Spaulding JT, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Eng J Med 1989;321:419- 424.
  • 20. Denis LJ, Whelan P, deMoura JCL, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853). Urology 1993;42:119- 132.
  • 21. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Eng L Med 1998; 339:1036-1042 .
  • 22. Tyrrell CJ, Kaisary AV, Iversen P et al. A randomized comparison of Casodex (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33:447-456.
  • 23. Iversen P, Tyrrell CJ, Kaisary AV, et al. Casodex (bicalutamide) 150 mg-monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer:results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998; 51:389-396.
  • 24. Boccardo F, Barichello M, Battaglia M, et al. Italian Prostate Cancer Group.Bicalutamide monotherapy versus Flutamide plus Goserelin in Prostate Cancer: Updated results of a multicentric trial. Eur Urol 2002; 42:481-490.
  • 25. Sciarra A, Cardi A, DiSilverio F. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer. Urol Int 2004; 72:91-98.
  • 26. Goldenberg SL, Bruchovsky N. Use of ciproterone acetate in prostate cancer. Urol Clin North Am 1991;18:111-112.
  • 27. Pavone-Macaluso M, de Voogt HJ, Viggiano G., et al. Comparison of DES, CPA and medroxyprogestrone acetate in the treatment of advanced prostatic cancer:final analysis of a randomized phase III trial of the European Organization for research on treatment of cancer urological group. J Urol 1986;136:624-631.
  • 28. Moffat LE. Comparison of Zoladex, DES and CPA treatment in advanced prostate cancer. Eur Urol 18(Suppl 3):26-27.
  • 29. Thorpe SC, Azmatullah S, Fellows GJ, O’Boyle PJ. A prospective, randomized study to compare goserelin acetate versus cyproterone acetate versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 1996; 29:47-54.
  • 30. Appu S, Lawrentschuk N, Grills RJ, Neerhut G. Effectiveness of CPA in achieving castration and preventing LHRH analogue induced testosterone surge in patients with prostate cancer. J Urol 2005;174:140- 142.
  • 31. Schröder FH, Whelan P, de Reijke TM, et al. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the EORTC protocol 30892. Eur Urol 2004;45:457-464.
Toplam 31 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Makaleler
Yazarlar

Yaşar Beduk Bu kişi benim

Nural Bekiroğlu Bu kişi benim

Atif Akdaş Bu kişi benim

Haluk Özen Bu kişi benim

Tarık Esen Bu kişi benim

Cavit Can Bu kişi benim

Levent Türkeri Bu kişi benim

Yayımlanma Tarihi 25 Haziran 2015
Yayımlandığı Sayı Yıl 2007 Cilt: 20 Sayı: 2

Kaynak Göster

APA Beduk, Y., Bekiroğlu, N., Akdaş, A., Özen, H., vd. (2015). METASTATİK PROSTAT KANSERİNDE CYPROTERONE ACETATE VE KASTRASYON MONOTERAPİLERİNİN ETKİNLİĞİNİN KARŞILAŞTIRMASI: ÇOK MERKEZLİ BİR TÜRK ÜRO-ONKOLOJİ GRUBU ÇALIŞMASI. Marmara Medical Journal, 20(2), 75-84.
AMA Beduk Y, Bekiroğlu N, Akdaş A, Özen H, Esen T, Can C, Türkeri L. METASTATİK PROSTAT KANSERİNDE CYPROTERONE ACETATE VE KASTRASYON MONOTERAPİLERİNİN ETKİNLİĞİNİN KARŞILAŞTIRMASI: ÇOK MERKEZLİ BİR TÜRK ÜRO-ONKOLOJİ GRUBU ÇALIŞMASI. Marmara Med J. Ağustos 2015;20(2):75-84.
Chicago Beduk, Yaşar, Nural Bekiroğlu, Atif Akdaş, Haluk Özen, Tarık Esen, Cavit Can, ve Levent Türkeri. “METASTATİK PROSTAT KANSERİNDE CYPROTERONE ACETATE VE KASTRASYON MONOTERAPİLERİNİN ETKİNLİĞİNİN KARŞILAŞTIRMASI: ÇOK MERKEZLİ BİR TÜRK ÜRO-ONKOLOJİ GRUBU ÇALIŞMASI”. Marmara Medical Journal 20, sy. 2 (Ağustos 2015): 75-84.
EndNote Beduk Y, Bekiroğlu N, Akdaş A, Özen H, Esen T, Can C, Türkeri L (01 Ağustos 2015) METASTATİK PROSTAT KANSERİNDE CYPROTERONE ACETATE VE KASTRASYON MONOTERAPİLERİNİN ETKİNLİĞİNİN KARŞILAŞTIRMASI: ÇOK MERKEZLİ BİR TÜRK ÜRO-ONKOLOJİ GRUBU ÇALIŞMASI. Marmara Medical Journal 20 2 75–84.
IEEE Y. Beduk, N. Bekiroğlu, A. Akdaş, H. Özen, T. Esen, C. Can, ve L. Türkeri, “METASTATİK PROSTAT KANSERİNDE CYPROTERONE ACETATE VE KASTRASYON MONOTERAPİLERİNİN ETKİNLİĞİNİN KARŞILAŞTIRMASI: ÇOK MERKEZLİ BİR TÜRK ÜRO-ONKOLOJİ GRUBU ÇALIŞMASI”, Marmara Med J, c. 20, sy. 2, ss. 75–84, 2015.
ISNAD Beduk, Yaşar vd. “METASTATİK PROSTAT KANSERİNDE CYPROTERONE ACETATE VE KASTRASYON MONOTERAPİLERİNİN ETKİNLİĞİNİN KARŞILAŞTIRMASI: ÇOK MERKEZLİ BİR TÜRK ÜRO-ONKOLOJİ GRUBU ÇALIŞMASI”. Marmara Medical Journal 20/2 (Ağustos 2015), 75-84.
JAMA Beduk Y, Bekiroğlu N, Akdaş A, Özen H, Esen T, Can C, Türkeri L. METASTATİK PROSTAT KANSERİNDE CYPROTERONE ACETATE VE KASTRASYON MONOTERAPİLERİNİN ETKİNLİĞİNİN KARŞILAŞTIRMASI: ÇOK MERKEZLİ BİR TÜRK ÜRO-ONKOLOJİ GRUBU ÇALIŞMASI. Marmara Med J. 2015;20:75–84.
MLA Beduk, Yaşar vd. “METASTATİK PROSTAT KANSERİNDE CYPROTERONE ACETATE VE KASTRASYON MONOTERAPİLERİNİN ETKİNLİĞİNİN KARŞILAŞTIRMASI: ÇOK MERKEZLİ BİR TÜRK ÜRO-ONKOLOJİ GRUBU ÇALIŞMASI”. Marmara Medical Journal, c. 20, sy. 2, 2015, ss. 75-84.
Vancouver Beduk Y, Bekiroğlu N, Akdaş A, Özen H, Esen T, Can C, Türkeri L. METASTATİK PROSTAT KANSERİNDE CYPROTERONE ACETATE VE KASTRASYON MONOTERAPİLERİNİN ETKİNLİĞİNİN KARŞILAŞTIRMASI: ÇOK MERKEZLİ BİR TÜRK ÜRO-ONKOLOJİ GRUBU ÇALIŞMASI. Marmara Med J. 2015;20(2):75-84.